-
公开(公告)号：EP3434668B1
公开(公告)日：2020-08-26
申请号：EP17769483.3
申请日：2017-03-24
申请人： Luoxin Pharmaceutical (Shanghai) Co., Ltd. , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
发明人： LU, Jianyu , DING, Charles Z. , HU, Lihong , HE, Huijun , CHEN, Shuhui , DONG, Jiaqiang , WANG, Tie-Lin
IPC分类号： C07D209/18 , C07D409/06 , C07D403/12 , A61K31/404 , A61P35/00
-
公开(公告)号：EP3766883A1
公开(公告)日：2021-01-20
申请号：EP19767751.1
申请日：2019-03-12
申请人： Luoxin Pharmaceutical (Shanghai) Co., Ltd. , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. , Medshine Discovery Inc.
发明人： CHEN, Kevin X , YAN, Xiaobing , HUANG, Jianglei , NIE, Yuekun , HU, Guoping , LI, Jian , CHEN, Shuhui , DONG, Jiaqiang , WANG, Tie-Lin
IPC分类号： C07D487/04 , A61K31/4188 , A61P35/00 , A61P31/04 , A61P31/12
摘要： Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. (I-1), (I-2)
-
公开(公告)号：EP3434668A1
公开(公告)日：2019-01-30
申请号：EP17769483.3
申请日：2017-03-24
申请人： Luoxin Biotechnology (Shanghai) Co., Ltd. , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
发明人： LU, Jianyu , DING, Charles Z. , HU, Lihong , HE, Huijun , CHEN, Shuhui , DONG, Jiaqiang , WANG, Tie-lin
IPC分类号： C07D209/18 , C07D409/06 , C07D403/12 , A61K31/404 , A61P35/00
摘要： Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.
-
公开(公告)号：EP3275882A1
公开(公告)日：2018-01-31
申请号：EP16767773.1
申请日：2016-03-24
申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
发明人： SHEN, Jingkang , MENG, Tao , YU, Ting , MA, Lanping , WANG, Xin , CHEN, Lin
IPC分类号： C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： Provided is a process of synthesizing a substituted pyridine and pyrimidine compound. Particularly, provided is a method for preparing a compound of formula III via a compound of formula II', wherein the definition of each of groups is as described as the description. Compound with other methods, the method in the present invention has features of high yield and a result product being easier to separate.
摘要翻译： 提供了合成取代的吡啶和嘧啶化合物的方法。 特别地，提供了通过式II'化合物制备式III化合物的方法，其中每个基团的定义如说明书所述。 与其他方法化合物相比，本发明方法具有收率高，结果产物易于分离的特点。
-
5.发明公开
公开(公告)号：EP3889136A1
公开(公告)日：2021-10-06
申请号：EP19888746.5
申请日：2019-10-17
申请人： Luoxin Pharmaceutical (Shanghai) Co., Ltd. , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
发明人： HE, Huijun , SHI, Shenyi , LU, Jianyu , DING, Charles Z. , HU, Lihong , SHI, Bin , YANG, Wenqian , DONG, Jiaqiang , WANG, Tie-Lin
IPC分类号： C07D209/18 , A61K31/404 , A61P35/00
摘要： Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor.
-
公开(公告)号：EP3712143A1
公开(公告)日：2020-09-23
申请号：EP18876913.7
申请日：2018-11-12
申请人： Luoxin Pharmaceutical (Shanghai) Co., Ltd. , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
发明人： WU, Chengde , HUANG, Jingjie , YU, Tao , DONG, Jiaqiang , WANG, Tie-Lin , LI, Jie , LI, Jian , CHEN, Shuhui
IPC分类号： C07D401/04 , C07D401/14 , C07D417/14 , C07D409/14 , C07D405/14 , A61K31/517 , A61P35/00
摘要： The present invention relates to a series of quinazolinone compounds and applications thereof as PI3Kα inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.
-
公开(公告)号：EP3275882B1
公开(公告)日：2020-09-23
申请号：EP16767773.1
申请日：2016-03-24
申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
发明人： SHEN, Jingkang , MENG, Tao , YU, Ting , MA, Lanping , WANG, Xin , CHEN, Lin
IPC分类号： C07D471/04 , C07D519/00
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
